






The medicinal uses of metals have been reported for almost 
5000 years, where in around 3000 BC Egyptians used copper to 
sterilize water, in 2500 BC Ancient China and Arabia used gold-
based medicines and in around 1500 BC the Egyptians were 
reported to use iron and zinc remedies to promote the healing of 
wounds.[1] However, the use of metals in medicinal chemistry 
was neglected until the 1900s, when potassium dicyanoaurate 
(Figure 1, 1) was first reported for its use in tuberculosis, and a 
small number of compounds were reported for their 
leishmaniasis (disease caused by parasites of the Leishmania 
type) and antibacterial activities. In 1909, Paul Ehrlich first 
discovered the antisyphilitic activity of the drug arsphenamine 
(Salvarsan), an arsenic containing compound, (2).[2] This 
organoarsenic compound was the first modern 
chemotherapeutic agent, however, it was thought to contain an 
As=As double bond, until 2005, when after extensive mass 
spectrometric analysis, the structure was confirmed to have As–
As single bonds and exist as a mixture of cycloarsenic rings, 
with three and five arsenic centres.[3] It was not until 1952 when 
Dwyer reported the bacteriostatic and bactericidal activity of 
cobalt and ruthenium compounds,[4] that the field of 
bioinorganic chemistry began to rapidly expand. 
There have been only few major breakthroughs in the use 
of metals in medicine, and this work stemmed from the 
discovery of the unexpected therapeutic effects of cis-
diamminedichloridoplatinum(II) (cisplatin or CDDP) (CDDP, 
3). This compound was first described by Michele Peyrone in 
1845 and known as Peyrone’s salt,[5] though it was the work by 
Rosenberg et al. in 1965 that brought CDDP into the 
spotlight.[6,7] The group were studying electrolysis, when it was 
noted that the platinum electrodes generated a platinum species 
which arrested the cell division of Escherichia coli (E. coli). The 
square planar compound, cis-[PtCl2(NH3)2], was later found to 
be effective at inhibiting the development of mass sarcomas in 
rats, and after several clinical studies it was approved for use in 
ovarian cancers, and the Food and Drug Administration (FDA) 
approved it in 1978 as Platinol®. To date, this compound is the 
most effective inorganic compound in the clinic, and is still used 
in the treatment of ovarian, testicular, lung and bladder cancers, 
as well as lymphomas, myelomas and melanoma.[8] However, 
CDDP is well documented to be non-specific for cancers and its 
continued use is greatly inhibited by dose limiting side effects 
and intrinsic or acquired drug resistance.[9–11] Such aspects 
sparked research towards new platinum-based therapeutics, 
which have lower toxicity towards normal cells types and can 
treat CDDP-resistant tumors. Although the platinum metal 
compounds make up the majority of the metal drugs within the 
clinic, much research has been aimed towards new transition 
metal compounds with lower cytotoxicity towards normal cell 
types. 
Organometallic arene compounds are metal complexes 
containing at least one metal-carbon bond and/or an arene 
substituent. This class of compounds have shown much promise 
in the quest for new anticancer compounds, as unlike many of 
the platinum complexes, the use of organometallics offers a 
greater range of structural design, diverse stereochemistry and 
by effect ligand design can provide control over the kinetic 
properties.[12] Organometallic complexes such as metallocenes, 
half-sandwich complexes, carbenes-, and both CO- and π- 
ligands have been widely studied for many transition metals.[12] 
After the discovery of the well-known ruthenium compounds, 
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Abstract 
In the past decade, libraries of iridium organometallic arene 
compounds have expanded rapidly, with the majority of their 
applications aimed towards effective catalysts and potential 
anti-cancer drug candidates. Researchers have begun to adapt 
the traditional “piano-stool” structures to include different 
bidentate ligands, ancillary ligands and extend the aromaticity 
and functionality of the arene substituent, all in the hope to 
optimize their activities and allow the determination of structure 
activity relationships. Many of the complexes incorporate N- 
and O-donor ligands, but more recently, these structures have 
been expanded to include C-donor ligands such as 
cyclometalated bidentate ligands and N-heterocyclic carbenes. 
This mini-review highlights the recent and ongoing research in 
C-donor iridium arene complexes, and discusses their 




NAMI-A (4) and KP1019 (5),[13–15] many ruthenium 
organometallic arene complexes were reported,[16,17] and 
analogous iridium complexes were designed based on their 
structures. After platinum, the ruthenium libraries have been the 
largest class of metal-based compounds studied, and it has only 
been in the past 10 years when the therapeutic potential of 
iridium organometallic complexes have been become 
apparent.[18,19] Iridium(III) is often considered one of the most 
inert metal ions, partly due to the reported inert nature of the 
low-spin d6 metal ion, with the water ligand exchange of 
[Ir(H2O)6]
3+ reported to take hundreds of years,[20] whilst 
[Cp*Ir(H2O)3]
2+ is approximately 1014 times faster.[21] This is 
potentially important and desirable for drug design. The ligands 
surrounding the iridium metal ion play a large role in the 
compound’s stability and may be of importance to the biological 
targeting.[22]  
Figure 1. Structures of early inorganic therapeutics 1-2 and the most 
prominent inorganic drug cisplatin (CDDP) 3, and prominent drug 
candidates NAMI-A 4 and KP1019 5. 
There have been numerous reports of both iridium(I) and 
iridium(III) complexes containing N-,[23–50] O-,[51–61] P-[62–65] and 
S-donor[66–71] ligands, dimeric species,[33,72,73] mononuclear 
scaffolds[74–79] and sandwich complexes,[80–82] which have shown 
significant potential in the quest for new anticancer therapeutics. 
There have been several reviews on non-arene iridium 
complexes which incorporate a range of C-donor ligands,[19,83] 
however, due to the increased focus on iridium arene complexes 
over the past 5 years, this review will highlight this emerging 
research fields of cyclometalated and N-heterocyclic carbene 
iridium arene complexes as potential drug candidates. 
Iridium(I) compounds 
The first organometallic iridium compounds to be reported 
for their therapeutic activity were d8 iridium(I) complexes 
[Ir(COD)(acac)] (Figure 2, 6) and [IrCl(COD)]2 (7) (COD = 
1,5-cyclooctadiene, acac = acetylacetone).[84,85] in which these 
square planar structures are similar to that of CDDP. Along with 
its rhodium analogues, these compounds were proven to be 
effective in the inhibition of subcutaneous tumor growth, 
however, they had low effects on lung metastases.[86] The 
findings were attributed to the rapid oxidation to the kinetically 
inert iridium(III), which leads to its inactivation. However, 
when tested in mice bearing Ehrlich ascites, compound 6 gave 
100% cures and inhibited growth of subcutaneous Lewis lung 
carcinoma in mice, whilst compound 7 showed anti-metastatic 
activity in the Lewis lung model, but no inhibition of primary 
tumors.  
Figure 2. Promising iridium(I) N-heterocyclic carbenes 6-16. 
More recently, research has been aimed at changing the 
bidentate ligands to include N-heterocyclic carbenes (NHCs). 
This is mainly due to the neutral nature of the ligands, which 
allows for both charged complexes to be formed, as well as the 
ability to stabilize low oxidation state iridium. This work began 
in 2013 when Simpson et al. synthesized a range of iridium(I) 
NHC compounds containing sulfonate or phosphonium groups 
(8 and 9).[87] The compounds bearing a terminal phosphonium 
group (9), which has properties of delocalized lipophilic cations, 
showed a > 4-fold increase in activity against breast 
adenocarcinoma (MDA-MB 231, IC50 values = 24 to 30 µM), 
when compared to the sulfonate analogues (IC50 values >100 
µM). However, the same compound is equitoxic against normal 
mouse fibroblasts (L929). Additionally, the cationic complexes 
exhibited low minimum inhibitory concentrations (MIC) against 
a range of bacteria, and an evaluation of the cellular metal 
accumulation clearly suggested a positive contribution of the 




In 2015, this work of iridium(I)-NHC complexes was 
extended by Gothe et al., who highlighted a new neutral 
iridium(I) COD compound which incorporated a bulky NHC 
substituent (10).[88] This compound exhibited only moderate 
activity against both breast adenocarcinoma (MCF7) and 
colorectal adenocarcinoma (HT-29, IC50 values = 14 to 19 µM), 
but also full inhibition of normal human embryonic kidney cells, 
(HEK-293T) at 30 M. Importantly, the compound formed 
adducts between cytochrome c, due to a loss of the ancillary 
chlorido ligand and a simultaneous oxidation of the Ir(I) to 
Ir(III). In 2016, the group extended the library to include bis-
carbene complexes (11).[89] These cationic complexes show 
more promise and higher activities, with complexes 11A-C all 
active in the high nanomolar range (IC50 values = 0.49 – 0.61 
µM (MCF7) and 0.26 – 0.47 µM (HT-29). Unlike the neutral 
complexes, which undergo rapid hydrolysis, the cationic 
complex has a high stability towards oxidation and only slow 
oxidation from Ir(I) to Ir(III) was observed in an excess of H2O2, 
and showing that the antiproliferative effects are not related to 
hydrolysis. Unlike the previously reported compound 10 which 
binds to cytochrome c and lysozymes by oxidation to Ir(III), the 
cationic complexes show no reaction with proteins. Alongside 
these new classes of complexes, work by Maftei et al. 
highlighted asymmetric (12) and symmetric (13) neutral 
iridium(I)-NHC trifluoromethylpyridine derivatives which 
surprisingly have no cellular activity, and IC50 values against all 
12 cell lines were > 100 µM.[90] More recently, triazole and 
thiazole-derived iridium(I) NHC complexes have emerged, (14-
16)[91] and exhibit significant interactions with model proteins 
and hexameric oligonucleotide ODN1. This highlights the 
necessity of fine-tuning of the ligand environment and a need to 
investigate structure-activity relationships. There continues to 
be ongoing research in the field of iridium(I) compounds as 
potential therapeutics, however, it appears their stability towards 
oxidation could remain an issue in further in vitro and in vivo 
assays. Thus, a significant proportion of iridium research has 
been aimed towards iridium(III) drug candidates. 
Iridium(III) compounds 
i) Cyclometalated C-donor complexes 
Most of the iridium(I) work incorporates COD moeties and 
there have been only few reports on iridum(III) COD complexes. 
To date, these complexes containing N,N-bidentate ligands and 
have yet to be expanded to include cyclometalated ligands or 
NHCs.[92–94] The main library of cyclometalated iridium 
complexes are based on the work by Sadler et al., where they 
have synthesized libraries of anionic C,N-donor ligands which 
are analogous to their previously published neutral N,N-donor 
ligands. Lui et al. first published and developed iridium(III) 
complexes containing neutral N,N-chelated bpy (bpy = 2,2’-
bipyridine) and the analogous anionic C,N-chelated ligands 
(Figure 3, 17 and 18), and showed for the first time that the 
iridium(III) C,N-donor complex was > 9-fold more cytotoxic 
against human ovarian cancer (A2780) when compared to the 
N,N-donor complex, which remained inactive.[95] Both of these 
complexes exhibit rapid hydrolysis in water and the C,N- 
complex has significant binding to 9-EtG and 9-MeA (96% and 
86% respectively), whereas the N,N-complex exhibits only 
moderate binding to 9-EtG (61%) and no binding to 9-MeA. 
Importantly, the group were the first to obtain single crystal X-
ray diffraction data for the C,N-complex with 9-EtG, showing 
binding at the N7 position of guanine (18A), highlighting their 
potential modes of action by DNA binding. Further work 
introduced functionality to the cyclopentadienyl moiety, Cpx 
(where x = Me, ph or biph (19B)), to increase the hydrophobicity 
and the ability of the systems to intercalate with DNA.[96] The 
complexes again undergo rapid hydrolysis and the active aqua 
adduct is the major form after hydrolysis at physiological pH. 
Above pH 8.7, the C,N- complexes form hydroxo-bridged 
dimers (19C), suggesting that they are less stable towards 
hydrolysis than the N,N- analogues. 
 
Figure 3. Selected iridium(III) N,N and C,N-donor complexes 17-23 
(the crystal structure is reproduced from the publications by Liu et 
al.,[95] with hydrogen atoms and solvent molecules omitted for 
clarity) 
Scheme 1 Pyridine complex 19A forms a glutathione adduct Ir-SG, 
which is oxidized by H2O2 to the sulfonato complex Ir-S(O)G and 
sulfinato complex Ir-S(O)2G (Liu and Sadler et al.
[97]) 
It has been shown that both electronic and steric properties 
of the bidentate ligands can have a large effect on the chemical 
and biological activities,[96,98,99] with electron-donating groups 
showing the largest increase in anticancer activity.[100] Amongst 
others, complex 18 was studied for its interaction with 
calmodulin, a calcium-binding protein found in the cytoplasm of 
all eukaryotic cells.[101] The degree of binding was elucidated by 
electron-capture dissociation (ECD)-based tandem mass 
spectrometry, and fragments were observed for MET (tyrosine 
kinase receptor) binding, although the strength of binding was 
relatively weak. This is the first mass spectrometry evidence of 




protein binding sites. Additionally, unlike CDDP which binds 
and displaces all four monodentate ligands, the iridium 
complexes do not readily lose the Cpx moiety of the chelating 
ligand. 
Extensive studies have been conducted using Cpbiph iridium 
C,N-complexes which have a variety of benzyl and pyridine 
functionalities[99] and labile Ir-X ligands,[100,102] whereby the 
pyridine complex 19A showed the highest potency and exhibits 
nanomolar activity.[22] The NCI 60 results show comparable or 
higher activity than the clinical drugs oxaliplatin (OXA) and 
CDDP, with complex 19A being 6-13 times more active than 
CDDP. This complex was also the first iridium species shown 
to generate high levels of reactive oxygen species (ROS) in 
cancer cells, and is 13 times more potent in cancer cells when 
compared to normal cells human lung fibroblast cells (MRC-
5).[103] Interestingly, the accumulation in ovarian cells (A2780) 
after just 24 hours was 20 times higher for complex 19A when 
compared to the analogous chloride complex 19B. Though the 
reaction with glutathione (GSH) was faster with 19B, the 
pyridine complex 19A formed a glutathione adduct Ir-SG, and 
due to the slower reaction it led to less deactivation of the 
complex. When the coenzyme NADH (2 equiv.) was added to a 
solution of Ir-SG, the NADH was oxidized to NAD+ and ~ 34% 
of the Ir-SG complex was oxidized to the sulfonato complex Ir-
S(O)G.[97] Following their previous catalytic studies of iridium 
and NADH to produce H2O2,
[103] the group reported that the 
H2O2 is indeed responsible for the oxidation to Ir-S(O)G and in 
excess H2O2 the complex oxidized further to the sulfinato 
complex, Ir-S(O)2G (Scheme 1).  
More recently, analogous complexes of 18 were 
synthesized to incorporate BODIPY moieties in the ancillary 
ligand position, whereby complex 20 not only exhibited high 
quantum yields, but had high potential against a range of cell 
lines.[104] In particular this complex was more hydrophobic and 
25 times more active than complex 18 against human ovarian 
cell line A2780. The addition of BODIPY allows for a more 
complete understanding of the cellular uptake, accumulation and 
distribution within the cells by using the complex’s excellent 
photophysical properties, which in turn could provide further 
mechanistic understanding of both platinum and non-platinum 
drug candidates. Complex 20 exhibits a sharp absorption peak 
at 505 (ε = 74 900 M-1 cm-1), and a fluorescence emission band 
at 514 nm, which is similar to free meso-pyridyl-BODIPY 
ligands. There was a small amount of photodissociation and 
photobleaching observed, but to a lesser extent than is observed 
for mono pyridine-based ligands. Upon incubation with MDA-
MB-231 cells, fluorescence emission was observed, with small 
spots visible in the cells cytoplasm, giving evidence that the 
compound was able to permeate the cell. Due to the 
photostability of these BODIPY complexes, the uptake was 
measured in live cells, and reached maximum emission intensity 
in just 90 seconds. This work highlights the significant potential 
fluorescent molecules and probes can have on the understanding 
of the compounds’ modes of action. 
Along with the rhodium analogue, an iridium(III) steroidal 
complexes containing LEV-ppy (2-phenylpyridyl-4-ethynyl]-
19-nortestosterone, 21) was synthesized and exhibited ~6-fold 
high potency against human breast cancer cell line (T47D) than 
CDDP and was approximately twice as active as the non-
steroidal analogue.[105] The complexes also had higher potencies 
against the CDDP resistant ovarian cancer cell line (A2780cis), 
with resistance factors ranging 0.9-1.1. Unlike CDDP, which 
remains only moderately cytotoxic against this cell line, this 
complex has a high resistance factor of 15.7. These complexes 
interact with CT-DNA and are cathepsin B inhibitors. 
Figure 4. A range of cyclometalated benzimidazole and Schiff base 
complexes 24-28 
The cyclometalated bidentate C,N-ligands have been 
extended to include functionalized arene rings,[99,102] reports by 
Novohradsky et al. showed that the neutral N,N-compound 22 
are inactive (IC50 > 100 M) against ovarian and breast 
carcinomas, whereas the cationic C,N-compound 23 exhibited 
potency similar to CDDP against the ovarian cell lines, A2780 
and A2780cis.[106] Upon assessing the cellular accumulation, it 
was noted that energy-passive diffusion plays a significant role, 
and the amount of uptake was enhanced by the depletion of 
intracellular ATP.  
A range of C,N-cyclometalated benzimidazole compounds have 
been shown to have good activity against a range of cell lines, 
with compound 24 (Figure 4) exhibiting > 9-fold increase in 
potency when compared to CDDP (HT-29; IC50 (24) = 0.98 ± 
0.02 M and IC50 (CDDP) = 9.5 ± 0.2 M).[107] Compound 24 
displays ca. 2–3 more metal accumulation than that found for 
CDDP.[108] The complexes also induce high levels of apoptosis, 
S-phase cell arrest, strong binding to HSA and also weakly bind 
to DNA at the minor groove. This library was extended to 
include different R substituents, whereby the benzyl group, 25, 
showed increased potency against a range of cancer lines.[109] 
However, the ruthenium p-cymene analogues remained more 
active than the analogous iridium compounds.[109] Compound 21 
increased the degree of ROS in A2780 cells (at 2 mM), though 
the metal content in nuclear DNA was low. 
Iridium(III) Cp* complexes containing functionalized 
Schiff base benzylidene ligands (26) have been reported, with 
complexes exhibiting effective binding to DNA either through 
intercalation and/or electrostatic interactions or through the 
display of covalent bonds.[110] With the addition of 
computational docking, it was found that these compounds bind 
within the minor groove of DNA, by insertion of the imine into 
a range of hydrophobic residues, through electrostatic 
interactions. The complex with a methoxy substituted ligand 
exhibited high nanomolar potency against chronic myelogenous 
leukemia, K562 (IC50 = 0.26 M), with apoptosis studies 
showing an induction of apoptosis and an increase in ROS on 
decreasing MMP (mitochondrial membrane potential).[111] On 
analysis of the gene expression when K562 cells were treated 
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with this complex, there was an upregulation of Bax and 
caspase-9 and a downregulation of Bcl-2 and release of 
cytochrome c, all suggestive of apoptosis through intrinsic 
mitochondrial apoptosis pathways.  
Additional adaptations were made of the benzylidene 
ligand to include naphthyl (27), which showed high activity 
against human ovarian carcinomas (A2780 and A2780cis) and 
remaining relatively non-toxic towards human embryonic 
kidney (HEK) cells. These systems were extended into 
poly(propyleneimine) dendrimer scaffolds in which the 
octanuclear chelating iridium metallodendrimer (28) shows 
superior activity in cancerous cells, when compared to the 
analogous mononuclear complexes 27, however, they remain 
cytotoxic towards normal cell types.[112] 
Sadler et al. have conducted research on the effects the 
arene substituent has on the systems. Interestingly, the cytotoxic 
values usually follow a trend, whereby the number of phenyl 
rings attached to the Cpx moiety increases the activity, Cpbiph > 
Cpph ≫ Cp*. Liu and Sadler have reviewed these trends, and 
clearly show that increase in hydrophobicity of complexes leads 
to increased cell entry, higher in vitro activity, a higher degree 
of intercalation with DNA and a high Keq for hydrolysis.
[22] 
Therefore, modifications of the previously described complexes 
could increase the complexes’ cellular activities and aid in more 
effective drug development. 
ii) Carbene C-donor ligands 
Though much work is being conducted on iridium(I) NHCs, 
the work on iridium(III) NHCs has only just been emerging 
within the last five years. To date four classes exist, which are 
(i) monodentate C-, (ii) bidentate C,C-, (iii) heteronuclear C,N- 
and (iv) C,O-donor ligands, of which a selection are shown in 
Figure 5. The first class of monodentate iridium(III) were 
synthesized in 2016, Schmitt et al., in which they reported 
histidin-2-ylidene 29 and imidazol-2-ylidene 30, however, the 
library of iridium complexes were non-toxic against all cell lines 
tested.[113]  
The second class are the bis-carbene complexes, of which 
the first were reported in 2017 by Wang et al.[114] Eleven new 
complexes showed good anticancer activity, with several 
complexes exhibiting equitoxic potency when compared to 
CDDP against human cervical cancer cells, HeLa. Also, when 
the arene ring is Cpbiph and the imidazole functional groups 
included butyl (31A) or phenyl (31B), the complexes were 2.2- 
and 2.5-fold more potent than CDDP, respectively. The 
complexes undergo hydrolysis, and the slower hydrolysis was 
linked to potency. They also display no binding to 9-EtA and 
9-EtG, yet they showed apoptosis, and several complexes 
inhibited the cell cycle in the G1 and G2/M phase whilst 
inducing high levels of ROS. Of the class of C,C-donors, Han et 
al. have reported functionalized phenyl NHC complexes which 
are all cytotoxic with complex 32 exhibiting high activity 
towards human lung carcinoma A549, which are 3-5-fold more 
cytotoxic than CDDP.[115] On analysis of the cell cycle, the 
complexes exhibit a disturbance in the sub-G1 or S phase, 
suggesting that these complexes have an effect on the growth 
cycle progression and can cause apoptosis, whilst inducing ROS. 
The subcellular localization in A549 cells was determined by 
confocal microscopy, and highlights an energy dependent 
mechanism of uptake.  
Two reports have been made on iridium(III) imine-N-
heterocyclic carbenes, with the first from Yang et al.[116] A range 
of complexes with varying alkyl and aryl derivatives have been 
synthesized and show high activities when tested against A549. 
In particular, complex 33 is > 10.7-fold more cytotoxic than 
CDDP, and has detectable fluorescence. No nucleobase binding 
was observed for all complexes, ruling out modes of action 
which involve DNA, though they reacted with GSH, catalyze 
the oxidation of NADH to NAD+ and had moderate binding to 
BSA. Additional studies revealed a decrease in mitochondrial 
membrane potential and a disruption of the G2/M phase in the 
cell cycle, with an overall induction of apoptosis and the most 
active complex 33 also induced high levels of ROS. Upon 
analysis of the confocal images, complex  was found to enter 
the cells mainly by an energy-dependent pathway, and was 
located in the lysosome.  
Figure 5. A range of N-heterocyclic carbene complexes 29-35 
 
Another library of complexes was reported by Han et al., 
which incorporate benzimidazole NHC ligands.[117] Complexes 
such as 34 were shown to exhibit activities up to 5-fold higher 
than CDDP when tested against A549 cells. As with the previous 
library of complexes, these benzimidazole complexes 
effectively bind with BSA, catalyze the oxidation of NADH to 
NAD+, and induce ROS which leads to apoptosis. They also 
target lysosomes and mitochondria, and enter the cell through an 
energy-dependent mechanism. 
Lastly, the group of Zhang et al. designed a library of C,O-
donor phenoxide chelated iridium(III)-NHC complexes (35), 
which show activity towards both A549 and cervical 
adenocarcinoma, HeLa.[118] The complexes hydrolyzed but 
displayed no binding to 9-MeA and 9-EtG and no cleavage to 
pBR322 plasmid DNA and showed only little binding affinity to 
CT-DNA. Like the C,N and C,C class of complexes, they 
interfere with NADH/NAD+ hydrogen transfer and increase 
levels of ROS. Complexes were shown to either influence the 
cell cycle at the G0/G1 phase, or induce apoptosis and 
mitochondrial dysfunction. Only a small amount of binding to 
CT-DNA was observed, suggesting DNA is not a primary target, 




observed, and may contribute to their activity against these 
cancer cells. 
iii) Assemblies for delivery 
Using the structure of complex 18, cyclic peptide-polymer 
conjugates have been designed and synthesized (Figure 6, 36), 
and provide a drug delivery system for the iridium(III) 
anticancer complexes. In 2018, Larnaudie et al. functionalized 
2-hydroxypropyl methacrylamide (HPMA) by copolymerizing 
with a pyridine-containing monomer, which provided effective 
binding to the iridium metal center of complex 18.
[119]
 The 
copolymer was conjugated to self-assemble cyclic peptides to 
form nanotubes, and when tested against human ovarian cells 
A2780, they exhibit equitoxicity or increased toxicity compared 
to the free drug. The nanotubes also exhibit lower toxicity 
against normal human ovarian fibroblasts (HOF) when 
compared to the free drug. Upon analysis of the metal content 
inside the cells after equimolar incubation, the nanotubes and 
free drug exhibit similar percentages of metal, showing that the 
nanotube did not increase drug uptake, however, with the 
decrease in toxicity towards normal cell types, the nanotubes 
could provide a more efficient mode of action and could lead to 
improved delivery of inorganic drugs into the body. 
Figure 6. Cyclic peptide-polymer conjugates containing iridium(III) 
cyclometalated complexes, 36 
Conclusions 
Though there are many interesting and effective iridium(I) 
complexes, their use as potential anticancer compounds is 
significantly limited by the oxidation of the complexes from Ir(I) 
to Ir(III). This change in oxidation state can cause the 
compounds to become inactive, or result in decomposition of the 
complex, making the therapeutic effects less pronounced. It can 
be concluded that iridium(III) compounds remain the most 
effective compounds, as their oxidation states are stable in 
aqueous medium, and the ease of synthesis allows for a more 
comprehensive library of compounds to be designed.  
We have highlighted compounds with only a small range 
of cyclometalated and N-heterocyclic carbene ligands, however, 
there are numerous modifications which can be made to improve 
the cytotoxicity of these libraries. To date, there is no such C-
donor ligand design which appears to be superior, though with 
the extensive work conducted on the anionic C,N-donor 
bipyridine analogues by Sadler et al. and their excellent in vitro 
potency, we believe these ligands to be the most effective ligand 
choice. Also, a key design feature which appears to be effective 
in increasing cytotoxicity is the addition of hydrophobic groups 
to the Cpx ring. The most promising of all the substituents is the 
addition of a biphenyl (Cpbiph) ligand, in which the iridium 
compounds incorporating these ligands have generally shown a 
higher cellular uptake, increased ROS and exhibit nanomolar 
potency. 
This review only highlighted two compounds which have 
been designed to incorporate anionic (sulfonate) and cationic 
(phosphonium) ligands, however, the cationic compound 
exhibits a > 4-fold increase in activity when compared to the 
anionic compound. These compounds are iridium(I) COD 
compounds, and cationic versus anionic studies have not yet 
been conducted for the iridium(III) C-donor compounds. Similar 
work has been reported on iridium(III) N,N-donor compounds, 
in which Zhang et al. have shown that changing the anionic 
counterion can exhibit up to a 9-fold increase in cytotoxicity.[101] 
This field of research could highlight new potential drug leads 
for the iridium(III) libraries, by incorporation of either cationic 
or anionic functional groups or changing the anionic counterion. 
Two of the most promising features of drug design which 
have the potential to excel in clinic therapeutics are the use of 
fluorescent probes such as BODIPY and the encapsulation of the 
compounds into a polymeric design. The use of a probe can help 
to determine the cellular uptake and modes of action of the 
compounds, whilst the use of polymers can help to protect and 
stabilize the compound from degradation and deliver it to the 
active site within a cellular environment. Coupled together in 
one system, a fluorescent polymer which encapsulates iridium, 
or a polymer which encapsulates fluorescent iridium, are smart 
structural designs for the future of transition metal drug 
discovery and delivery, and will undoubtedly be a hot topic for 
future research platforms. 
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Organometallic iridium compounds: the effects of C-donor ligands on anticancer activity 
 
To date, the most effective iridium anticancer compounds are those with “piano-stool” structures and which usually incorporate a variety of N-, O-, S- 
and P- bidentate ligands. These compounds can be easily functionalized by changing the bidentate ligands, the ancillary ligands and increasing the 
aromaticity of the arene substituent, all in the hope to optimize their activities and allow the determination of structure activity relationships. However, 
research towards C-donor ligands has only just emerged in the past 5 years, with cyclometalated and N-heterocyclic carbene iridium complexes showing 
significant increases in potency towards a range of cancer cell lines. This mini-review highlights the recent and ongoing research in C-donor iridium 
organometallic complexes, and herein we discuss their importance as potential anticancer drugs. 
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